Clive Lovelday is a Consultant in Sexual Health with 31 years of experience in the management of sexual transmitted diseases, HIV and associated viral infections. He is currently Consultant for Buckinghamshire Community Sexual Health and HIV, Honorary Consultant for Buckinghamshire NHS Trust and Clinical Lead for International Clinical Virology Centre (ICVC) Charitable Trust. He graduated from Middlesex Hospital, University of London and undertook his postgraduate training in STD/HIV and Virology at University College Hospital and Primary Health Care at Norfolk and Norwich University Hospital.
He worked as a clinician and research fellow at one of the leading centres in the world for STD/HIV from the early days of HIV/AIDS. In 1996 he was appointed the first UK Professor of HIV/AIDS at Royal Free Hospital Medical School where he established a department to apply molecular virological technology to support the care of patients with HIV and hepatitis. In 2001 he established the ICVC Charitable Trust and Clinic to support the clinical care and treatment of patients with HIV and Hepatitis in 42 NHS district general hospitals across the UK. From 1988 onwards he has been the virology lead for a series of ground-breaking international MRC and EuroSIDA clinical trials establishing the treatment protocols for HIV/AIDS and the use of molecular virological measures to manage chronic virological infections.
Throughout his career he continued his hands-on care of patients with problems in sexual health, and managed the treatment of patients with HIV/AIDS and Hepatitis. He has GMC Higher Professional Registration in Clinical Microbiology (virology) and Primary Health Care.
He is currently Honorary Professor in Infectious Diseases at Thames Valley University and was recently awarded a lifetime DSc from University of West London for clinical and research contributions in the field of HIV/AIDS.
His research established National and International standards for the use of molecular virology to support diagnosis, monitoring and treatment of HIV/AIDS and other chronic viral infections. He has published over 150 peer-reviewed papers and over 200 abstracts in sexually transmitted diseases and chronic viral infections. Currently his team is developing technologies that will allow this level of clinical support for STD and HIV/AIDS to be devolved to resource-limited settings.